Table III.
Histopathological parameters and relative expression levels of ARHGDIB mRNA in all patients with RCC.
| Sample/pathology | Patients, n | Mean relative ARHGDIB expression (∆∆Cq) | Standard deviation |
|---|---|---|---|
| Total | 105 | ||
| Sex | |||
| Male | 67 | −0.43 | 1.04 |
| Female | 38 | −0.16 | 0.76 |
| Age | |||
| Below median (65 years) | 54 | −0.34 | 0.98 |
| Equal to or above median (65 years) | 51 | −0.32 | 0.93 |
| Histology | |||
| Papillary RCC | 28 | −1.29 | 0.97 |
| Clear cell RCC | 84 | −0.05 | 0.75 |
| M stage | |||
| M0 | 82 | −0.39 | 1.04 |
| M+ | 23 | −0.12 | 0.48 |
| N stage | |||
| N0 | 94 | −0.30 | 0.96 |
| N+ | 11 | −0.56 | 0.85 |
| Disease progressiona | |||
| Localized RCC | 76 | −0.36 | 1.04 |
| Advanced RCC | 29 | −0.24 | 0.68 |
| Grade | |||
| ≤2 | 88 | −0.30 | 0.91 |
| >2 | 17 | −0.52 | 1.15 |
a
Advanced RCC was defined as pT3-4 or N+ or M+ or grade >2. ARHGDIB, Rho GDP dissociation inhibitor-β; RCC, renal cell carcinoma; N+, positive lymph node metastasis; M+, positive organ metastasis.